Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Neijt

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
European Journal of Cancer & Clinical Oncology|April 1, 1988
Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in ratsR Gerritsen van der Hoop, P de Koning, E Boven, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1993
New cytostatic drugs in ovarian cancerH H Hansen, E A Eisenhauer, M Hansen, et al.
Journal of the Neurological Sciences|November 1, 1994
Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidenceR Gerritsen van der Hoop, F P Hamers, J P Neijt, et al.
British Journal of Cancer|January 1, 1995
Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative GroupJ P Neijt, A J Lacave, T A Splinter, et al.
Cancer Research|February 1, 1993
Reduced glutathione protects against cisplatin-induced neurotoxicity in ratsF P Hamers, J H Brakkee, E Cavalletti, et al.
Cancer|October 15, 1990
Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatinR G van der Hoop, M E van der Burg, W W ten Bokkel Huinink, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 30, 1991
[Ambulatory continuous intravenous infusion of fluorouracil: a feasible palliative form of chemotherapy]M E van Hoef, B A Zonnenberg, A de Graeff, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1989
Phase II trial of mitozolomide in patients with advanced ovarian cancer. A study of the EORTC Gynecological Cancer Cooperative GroupJ P Neijt, M E van der Burg, J P Guastalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1989
Predictability of the survival of patients with advanced ovarian cancerJ C van Houwelingen, W W ten Bokkel Huinink, M E van der Burg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 1993
Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group StudyB G Taal, R A Audisio, H Bleiberg, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
European Journal of Cancer & Clinical Oncology|April 1, 1988
Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in ratsR Gerritsen van der Hoop, P de Koning, E Boven, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1993
New cytostatic drugs in ovarian cancerH H Hansen, E A Eisenhauer, M Hansen, et al.
Journal of the Neurological Sciences|November 1, 1994
Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidenceR Gerritsen van der Hoop, F P Hamers, J P Neijt, et al.
British Journal of Cancer|January 1, 1995
Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative GroupJ P Neijt, A J Lacave, T A Splinter, et al.
Cancer Research|February 1, 1993
Reduced glutathione protects against cisplatin-induced neurotoxicity in ratsF P Hamers, J H Brakkee, E Cavalletti, et al.
Cancer|October 15, 1990
Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatinR G van der Hoop, M E van der Burg, W W ten Bokkel Huinink, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 30, 1991
[Ambulatory continuous intravenous infusion of fluorouracil: a feasible palliative form of chemotherapy]M E van Hoef, B A Zonnenberg, A de Graeff, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1989
Phase II trial of mitozolomide in patients with advanced ovarian cancer. A study of the EORTC Gynecological Cancer Cooperative GroupJ P Neijt, M E van der Burg, J P Guastalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1989
Predictability of the survival of patients with advanced ovarian cancerJ C van Houwelingen, W W ten Bokkel Huinink, M E van der Burg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 1993
Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group StudyB G Taal, R A Audisio, H Bleiberg, et al.
Pageof 10